Joshua Mali, MD
Joshua Mali, MD, is a vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida.
Dr. Mali's top 5 predictions in ophthalmology for 2018
Dr. Mali's top 5 predictions in ophthalmology for 2018
Josh Mali, MD, shares his predictions for the 2018 ophthalmic year.
Quarterly Questions is the new gold standard for board certification
Dr. Mali discusses how the Quarterly Questions program assesses fundamental (“walking around”) knowledge needed in the everyday practice of ophthalmology (40 questions annually), as well as the application of information from five journal articles (10 questions annually).
Dr. Mali's top 5 stories in ophthalmology in 2017 (so far)
So far, 2017 has been a very exciting year for both ophthalmology and healthcare as a whole. We still have a few months left for more excitement, so stay tuned!
Changing the game in treatment of acute pseudophakic CME
Joshua Mali, MD, provides clinical evidence and recommendations for pseudophakic CME and represents a new formal standard to first-line management.
Genetic testing initiative for inherited retinal diseases shows great promise
I have been encouraged as a retinal specialist with all the excitement and promising new treatments in gene therapy. Given that there are several retinal diseases with known inherited patterns and confirmed genetic loci responsible for the clinical manifestations, our field is primed to benefit from the expansion of knowledge in this arena.
New paradigm shift in selecting a steroid course prior to FAc implant
As retinal specialists, we are truly fortunate to live in a time where we have several treatment options for patients with diabetic macular edema (DME). A fluocinolone acetonide (FAc) intravitreal implant 0.19 mg (Iluvien, Alimera Sciences) is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.
Dr. Mali's top 5 predictions in ophthalmology for 2017
The great thing about making predictions is that it is basically a win-win proposition: if you are correct in your predictions, you are celebrated for being a sage. If you are incorrect, you have the opportunity to learn from them and make better predictions for the next year. Wishing everyone a Happy New Year and a successful 2017!
What ophthalmologists are thankful for
What ophthalmologists are thankful for
As we sit down together with our families and friends for Thanksgiving dinner this year, we thought reflecting on the great innovations in the field of ophthalmology since the turn of this new century seemed timely (a topic that is a natural by-product of the marriage between a retinal surgeon and a pediatric ophthalmologist!).
Time for a paradigm shift in the treatment of DME
Well tolerated and effective, anti-VEGF therapy is the current gold standard to treat DME. However, one treatment simply does not fit all and VEGF may just be one piece of a much larger puzzle. The fact that some DME patients have a limited response to anti-VEGF therapy is representative of this concept; we are discovering that there are additional inflammatory mediators that may be crucial components to the DME picture.
Selecting the right DME patients for long-term steroidal implants
An increasing number of treatment options have given patients facing diabetic macular edema (DME) new hope in the face of this chronic, progressive, and blinding disease. Experience and time have shown us there is not a one-size-fits-all solution for patients with DME. To get the results we want, we need to screen our patients and match them with the treatment protocol best suited to their needs.
var script= ' ';